OPDP takes an integrated approach to ad reviews

Share this article:

Pharma marketers and their agencies have been talking forever about shedding the silos that house their consumer- and professional-facing promotional efforts. Now FDA is getting in on the game.

The agency's Office of Prescription Drug Promotion used to have separate divisions for consumer and professional-facing promotion. Now, they're shuffling the deck to form two divisions, organized around therapeutic categories, that will review both consumer and professional promotion.

“Recently, OPDP reviewed and analyzed the workload and review processes in its two divisions, the Division of Consumer Drug Promotion and the Division of Professional Drug Promotion, in an effort to improve upon their overall impact and effectiveness,” said Center for Drug Evaluation and Research head Janet Woodcock in a statement. “The goal of this analysis was to increase efficiency, improve work distribution and eliminate redundancy. Through the analysis, OPDP concluded that a structure that integrates the review of health care professional-directed and consumer-directed promotion across the two divisions would meet this goal.”

Pending approval, the Office will house two review groups, each composed of four teams assigned a therapeutic area. Division I, led by acting director Andrew Haffer, will tackle promotional materials for products in neurology/psychiatry; hematology; oncology; and analgesics, anesthetics and antivirals. Division II, led by director Robert Dean, will look at ads for treatments in osteoporosis, reproductive and urology; dental, dermatology, metabolic and endocrine; allergy, gastroenterology, pulmonary and rheumatology; and anti-infective, cardiovascular, medical imaging, ophthalmology, renal and transplant. Here's the org chart.

“We know that DTC advertising is often the catalyst for patients initiating conversations with their physicians about their untreated or undertreated conditions,” said Woodcock's statement.  It is also a subject of interest and debate among our stakeholders. The decision to restructure the divisions reflects our commitment to continue providing close oversight of DTC advertising. The new structure will improve efficiency in our program area and our ability to meet the health needs of the American public.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...